Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of MDCO-216 in healthy volunteers and stable coronary artery disease
NL-OMON39847Active, not recruiting
- Sponsor
- The Medicines Company
- Start
- Feb 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in atherosclerosis and coronary arteriosclerosis comparing MDCO-216 single ascending dose with Placebo (2 arms). Primary endpoint: Safety, tolerability and pharmacokinetics of escalating single doses of MDCO-216. Started Feb 2013; status: active, not recruiting.
02
Drugs
apolipoprotein A-I Milano
03
Conditions
atherosclerosiscoronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON39847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39847.